Welcome to our dedicated page for Dbv Technologies S A SEC filings (Ticker: DBVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A. filings document the disclosure record of a French late-stage biopharmaceutical issuer with American Depositary Shares listed under DBVT. The filings identify ordinary shares and ADSs, with each ADS representing five ordinary shares, and cover the company’s VIASKIN patch technology, epicutaneous immunotherapy approach, and food-allergy development programs.
Recent SEC materials include Form 8-K reports for operating results, business highlights, clinical-data releases for the Phase 3 VITESSE study, warrant-related financing events, and governance matters. Proxy materials describe shareholder meeting proposals, board and committee matters, executive compensation, and equity-award plans.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.
Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies, a clinical-stage biopharma company focused on food allergies, highlights a defining year led by positive topline Phase 3 VITESSE results for the VIASKIN® Peanut Patch in children aged 4 to 7 years. These data support a planned Biologics License Application submission in the United States in the first half of the year and underpin preparations for potential commercialization.
The company is also advancing the COMFORT Toddlers safety trial in children aged 1 to 3 years and THRIVE, a first-of-its-kind study in infants aged 6 to 12 months. DBV reports raising $386.2 million in capital between March 2025 and January 2026, providing funding into the second quarter of 2027, including the potential U.S. launch of the VIASKIN Peanut Patch.
The proxy statement convenes the 2026 Annual Combined General Meeting on June 3, 2026 in Châtillon, France, with 40 resolutions covering approval of 2025 financial statements, director elections and compensation, share buyback and cancellation authority, extensive capital-raising and merger/de-merger authorizations, equity incentive plans, and bylaw amendments such as setting the CEO age limit at 70 years.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies S.A. filed a proxy statement for its 2026 Annual Combined General Meeting to be held on June 3, 2026 in Châtillon, France and webcast live. The letter from management highlights positive topline results from the Phase 3 VITESSE trial of the VIASKIN® Peanut Patch in children 4–7 and plans to submit a Biologics License Application in the United States in the first half of 2026. Management reports initiation and progress on supplemental pediatric trials including COMFORT Toddlers and THRIVE in infants. The company raised $386.2 million between March 2025 and January 2026 and states this funding supports operations into the second quarter of 2027. Proxy materials, the 2025 Form 10-K, meeting agenda (40 proposals), board slate and governance materials will be mailed to ADS and ordinary shareholders in May 2026.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.